Clinical Trials Browser

Phase 3 × Active not recruiting × Fulvestrant × Clear all

NCT04650581 2026-04-13

FINER

Phase 3 Active not recruiting

250 enrolled 13 charts

Breast Neoplasms

NCT05038735 2026-04-08

EPIK-B5

Phase 3 Active not recruiting

Breast Neoplasms

NCT06764186 2026-04-08

CAPItana

Phase 3 Active not recruiting

Breast Neoplasms

NCT04851613 2026-04-02

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms

NCT06635447 2026-03-27

CAPItrue

Phase 3 Active not recruiting

Breast Neoplasms, Disease Progression

NCT00099437 2026-03-18

CONFIRM

Phase 3 Active not recruiting

736 enrolled 14 charts

Breast Neoplasms

NCT05654623 2026-03-18

VERITAC-2

Phase 3 Active not recruiting

624 enrolled 17 charts

Breast Neoplasms

NCT02947685 2026-02-12

PATINA

Phase 3 Active not recruiting

518 enrolled 15 charts

Breast Neoplasms

NCT05501886 2026-02-10

VIKTORIA-1

Phase 3 Active not recruiting

Breast Neoplasms, Neoplasm Metastasis

NCT02763566 2026-02-05

MONARCH plus

Phase 3 Active not recruiting

463 enrolled 20 charts

Breast Neoplasms

NCT05646862 2026-02-05

INAVO121

Phase 3 Active not recruiting

Breast Neoplasms

NCT05306340 2026-01-30

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

Phase 3 Active not recruiting

Breast Neoplasms

NCT04305496 2026-01-29

CAPItello-291

Phase 3 Active not recruiting

818 enrolled 19 charts 2 FDA

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT01953588 2026-01-22

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

Phase 3 Active not recruiting

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular

NCT05169567 2026-01-16

postMONARCH

Phase 3 Active not recruiting

368 enrolled 14 charts

Breast Neoplasms, Neoplasm Metastasis

NCT05365178 2026-01-07

To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer

Phase 3 Active not recruiting

HR-positive, HER2-negative Breast Neoplasms

NCT02107703 2025-10-21

MONARCH 2

Phase 3 Active not recruiting

669 enrolled 22 charts 1 FDA

Breast Neoplasms

NCT03425838 2025-09-19

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasm Female

NCT05063786 2025-09-08

ALPHABET

Phase 3 Active not recruiting

Breast Neoplasms

NCT04975308 2025-07-11

EMBER-3

Phase 3 Active not recruiting

874 enrolled 29 charts 3 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT05207709 2025-04-29

HARMONIA

Phase 3 Active not recruiting

Breast Neoplasms

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

Phase 3 Active not recruiting

Breast Neoplasms

NCT05077449 2024-05-24

A Study of XZP-3287 in Combination With Fulvestrant in Patients With Advanced Breast Cancer

Phase 3 Active not recruiting

Breast Neoplasms